{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T13:26:25Z","timestamp":1758893185005},"reference-count":23,"publisher":"Impact Journals, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2022,12,29]]},"DOI":"10.18632\/oncotarget.28333","type":"journal-article","created":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T14:32:46Z","timestamp":1672324366000},"page":"1370-1379","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Covid-19 on the management of patients with metastatic melanoma"],"prefix":"10.18632","volume":"13","author":[{"given":"Mich\u00e8le","family":"Welti","sequence":"first","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland"},{"name":"Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phil F.","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland"},{"name":"Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Mangana","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland"},{"name":"Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell P.","family":"Levesque","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland"},{"name":"Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Dummer","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland"},{"name":"Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurence","family":"Imhof","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University Hospital Zurich (USZ), Zurich 8091, Switzerland"},{"name":"Faculty of Medicine, University of Zurich (UZH), Zurich 8032, Switzerland"},{"name":"Institute for Biomedical Engineering, ETH Zurich, Zurich 8092, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2022,12,29]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Carbone","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2","doi-asserted-by":"publisher","first-page":"6049","DOI":"10.18632\/aging.103000","article-title":"Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis","volume":"1","author":"Huang","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"3","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/S0140-6736(20)31187-9","article-title":"Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study","volume":"39","author":"Peters","year":"2020","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"2","author":"Lee","year":"2020","journal-title":"Nat Med"},{"key":"5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"2","author":"Fittall","year":"2020","journal-title":"Lancet Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1080\/07357907.2020.1864129","article-title":"Challenges of Cancer Immunotherapy during the COVID-19 Pandemic","volume":"3","author":"Lyman","year":"2021","journal-title":"Cancer Invest"},{"key":"7","doi-asserted-by":"publisher","first-page":"e001931","DOI":"10.1136\/jitc-2020-001931","article-title":"Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition","volume":"9","author":"Vitale","year":"2021","journal-title":"J Immunother Cancer"},{"key":"8","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.3390\/cancers12082237","article-title":"Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?","volume":"1","author":"Libra","year":"2020","journal-title":"Cancers (Basel)"},{"key":"9","doi-asserted-by":"publisher","first-page":"e002835","DOI":"10.1136\/jitc-2021-002835","article-title":"Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors","volume":"9","author":"Turajlic","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"6071","DOI":"10.3390\/cancers13236071","article-title":"Melanoma Management during the COVID-19 Pandemic Emergency: A Literature Review and Single-Center Experience","volume":"1","author":"Quaglino","year":"2021","journal-title":"Cancers (Basel)"},{"key":"11","doi-asserted-by":"publisher","DOI":"10.5070\/D3274053169","article-title":"Changes in melanoma care practices during the COVID-19 pandemic: a multi-institutional cross-sectional survey","volume":"2","author":"Hartman","year":"2021","journal-title":"Dermatol Online J"},{"key":"12","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.jaad.2020.12.065","article-title":"The magnitude of COVID-19\u2019s effect on the timely management of melanoma and nonmelanoma skin cancers","volume":"8","author":"Rigel","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"13","doi-asserted-by":"publisher","first-page":"769368","DOI":"10.3389\/fmed.2021.769368","article-title":"Emerging Developments in Management of Melanoma During the COVID-19 Era","volume":"8","author":"Reuben","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"14","doi-asserted-by":"publisher","first-page":"e000509","DOI":"10.1136\/esmoopen-2019-000509","article-title":"How I treat metastatic melanoma","volume":"4","author":"Barysch","year":"2019","journal-title":"ESMO Open"},{"key":"15","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1053\/j.seminoncol.2020.07.010","article-title":"Data of Italian Cancer Centers from two regions with high incidence of SARS CoV-2 infection provide evidence for the successful management of patients with locally advanced and metastatic melanoma treated with immunotherapy in the era of COVID-19","volume":"4","author":"Queirolo","year":"2020","journal-title":"Semin Oncol"},{"key":"16","unstructured":"Kennzahlen zur Coronavirus-Pandemie in der Schweiz und in Liechtenstein, 2022_Q1, Stand: 28.02.2022, 08.17h. Bundesamt f\u00fcr Gesundheit. 2022."},{"key":"17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s40262-019-00748-2","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Immune Checkpoint Inhibitors","volume":"5","author":"van Hasselt","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"18","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.ejca.2020.09.028","article-title":"A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19","volume":"14","author":"n","year":"2020","journal-title":"Eur J Cancer"},{"key":"19","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1016\/j.annonc.2020.07.010","article-title":"Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus","volume":"3","author":"Tabernero","year":"2020","journal-title":"Ann Oncol"},{"key":"20","unstructured":"(CDC) CfDCaP. Science Brief: Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19. 2020. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK570436."},{"key":"21","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1245\/s10434-018-6513-7","article-title":"Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond","volume":"2","author":"Scolyer","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"108427","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: A review","volume":"21","author":"Koutsogiannaki","year":"2020","journal-title":"Clin Immunol"},{"key":"23","article-title":"Common Terminology Criteria for Adverse Events (CTCAE)","author":"Services USDoHaH","year":"2017","journal-title":"(CTEP Cancer)"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28333","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,29]],"date-time":"2022-12-29T14:32:50Z","timestamp":1672324370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.28333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,29]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12,29]]}},"alternative-id":["28333"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.28333","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,29]]}}}